{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:45:00Z","timestamp":1774032300203,"version":"3.50.1"},"reference-count":30,"publisher":"Scientific Scholar","issue":"03","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Lab Physicians"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Isepamicin is a 1-N-S-a-hydroxy-b-aminopropionyl derivative of gentamicin B and the spectrum of pathogenic microorganisms covered by it and its effectiveness is similar to that of amikacin except the action of aminoglycoside inhibitor enzymes is ineffectual on it.<\/jats:p><jats:p>\n          Material and Methods\u2003We performed a prospective study in the Bacteriology section of the Department of Microbiology at a 1,600-bedded hospital in Northern India from Jan 2022 to March 2022. Isepamicin was tested for susceptibility against gram-negative bacteria, identified by routine biochemicals and matrix-assisted-desorption\/ionization \u2013time of flight-mass spectrometry (MALDI-TOF-MS) assay. The antibiotic susceptibility testing for each of the isolates was performed by Kirby Bauer's disc diffusion method, according to the CLSI 2019 guidelines.<\/jats:p><jats:p>\n          Results\u2003The majority of isolates were obtained from blood samples (50, 39.1%). Among the non-inducible Enterobacteriaceae, Escherichia coli was least susceptible to amikacin (8\/27, 29.63%) and most susceptible to isepamicin (18\/27, 66.67%). Klebsiella pneumoniae followed the same pattern of susceptibility as E. coli and was least susceptible to Amikacin (20\/46, 43.48%) and most susceptible to isepamicin (24\/46, 52.17%). Enterobacter cloacae (6\/7, 85.71%) was most susceptible to both amikacin and isepamicin, followed by 71.43% (5\/7, 71.43%) susceptibility to gentamicin and tobramycin each. Enterobacter aerogenes was equally 53.33% (8\/15) susceptible to all antibiotics. Pseudomonas aeruginosa was the most susceptible isolate to all antibiotics (18\/21, 85.71%).<\/jats:p><jats:p>\n          Conclusion\u2003Isepamicin is a potential antimicrobial agent for treating an array of gram-negative bacteria-associated infections and shows better in vitro activity than older aminoglycoside agents.<\/jats:p>","DOI":"10.1055\/s-0043-1761928","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T23:49:12Z","timestamp":1679528952000},"page":"419-424","source":"Crossref","is-referenced-by-count":1,"title":["In-vitro Activity of Isepamicin against Gram-negative Bacteria in Comparison to Other Aminoglycosides Routinely used at a Teaching Hospital in Northern India"],"prefix":"10.25259","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1816-8891","authenticated-orcid":false,"given":"Tasneem","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9744-9653","authenticated-orcid":false,"given":"Mitra","family":"Kar","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-6110","authenticated-orcid":false,"given":"Akanksha","family":"Dubey","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-0729","authenticated-orcid":false,"given":"Sangram Singh","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-7717","authenticated-orcid":false,"given":"Chinmoy","family":"Sahu","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1179\/acb.2001.045","article-title":"Comparative in vitro activity of isepamicin and other antibiotics against gram-negative bacilli from intensive care units (ICU) in Belgium","volume":"56","author":"Belgian Isepamicin Multicenter Study Group","year":"2001","journal-title":"Acta Clin Belg"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/AAC.43.4.727","article-title":"Aminoglycosides: activity and resistance","volume":"43","author":"M P Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"S 02","key":"ref3","first-page":"17","article-title":"The most frequently occurring aminoglycoside resistance mechanisms\u2013combined results of surveys in eight regions of the world","volume":"7","author":"G H Miller","year":"1995","journal-title":"J Chemother"},{"issue":"S 02","key":"ref4","first-page":"31","article-title":"The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin\u2013a new broad-spectrum aminoglycoside","volume":"7","author":"G H Miller","year":"1995","journal-title":"J Chemother"},{"issue":"S 01","key":"ref5","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1093\/clinids\/24.Supplement_1.S46","article-title":"The most frequent aminoglycoside resistance mechanisms\u2013changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups","volume":"24","author":"G H Miller","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jac\/44.4.483","article-title":"Aminoglycoside resistance in gram-negative blood isolates from various hospitals in Belgium and the Grand Duchy of Luxembourg","volume":"44","author":"R Vanhoof","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"ref7","first-page":"329","article-title":"In vivo analysis of structure-activity relationships among four aminoglycosides: gentamicin, netilmicin, 1-N HAPA gentamicin B, and amikacin","volume":"26","author":"R V Goering","year":"1979","journal-title":"Curr Ther Res Clin Exp"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7164\/antibiotics.31.681","article-title":"The syntheses and biological properties of 1-N-(S-4-amino-2-hydroxybutyryl)-gentamicin B and 1-N-(S-3-amino-2-hydroxypropionyl)-gentamicin B","volume":"31","author":"T L Nagabhushan","year":"1978","journal-title":"J Antibiot (Tokyo)"},{"key":"ref9","first-page":"201","article-title":"Experimental and clinical studies of HAPA-B","volume":"33","author":"H Oshitani","year":"1985","journal-title":"Chemother"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000276162","article-title":"Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin","volume":"52","author":"M Takumida","year":"1990","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"issue":"09","key":"ref11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1046\/j.1198-743x.2001.00284.x","article-title":"The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey","volume":"7","author":"U Over","year":"2001","journal-title":"Clin Microbiol Infect"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/mdr.2005.11.330","article-title":"In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan","volume":"11","author":"N C Cheng","year":"2005","journal-title":"Microb Drug Resist"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1128\/AAC.06358-11","article-title":"In vitro antimicrobial susceptibility to isepamicin of 6,296 Enterobacteriaceae clinical isolates collected at a tertiary care university hospital in Greece","volume":"56","author":"S Maraki","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"09","key":"ref14","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","article-title":"Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections","volume":"40","author":"M E Falagas","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"M E Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"ref16","volume-title":"Clinical and Laboratory Standards Institute","author":"P A Wayne","year":"2019"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0891-5520(20)30753-4","article-title":"Epidemiology and clinical impact of gram-negative sepsis","volume":"5","author":"M A Martin","year":"1991","journal-title":"Infect Dis Clin North Am"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/clinids\/5.4.629","article-title":"Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy","volume":"5","author":"C S Bryan","year":"1983","journal-title":"Rev Infect Dis"},{"issue":"06","key":"ref19","first-page":"481","article-title":"In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections","volume":"40","author":"T Y Tsai","year":"2007","journal-title":"J Microbiol Immunol Infect"},{"issue":"S 02","key":"ref20","first-page":"47","article-title":"Once-daily versus multiple-daily dosing of aminoglycosides","volume":"7","author":"W A Craig","year":"1995","journal-title":"J Chemother"},{"issue":"01","key":"ref21","first-page":"1","article-title":"Antibiotics: action and resistance in gram-negative bacteria","volume":"35","author":"L K Siu","year":"2002","journal-title":"J Microbiol Immunol Infect"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1472-8206.2001.00020.x","article-title":"Comparison of two methods to obtain a desired first isepamicin peak in intensive care patients","volume":"15","author":"F Fauvelle","year":"2001","journal-title":"Fundam Clin Pharmacol"},{"issue":"S 02","key":"ref23","first-page":"7","article-title":"Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity","volume":"7","author":"R N Jones","year":"1995","journal-title":"J Chemother"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7164\/antibiotics.31.688","article-title":"Biological activity of SCH 21420, the 1-N-S-alpha-hydroxy-beta-aminopropionyl derivative of gentamicin B","volume":"31","author":"G H Miller","year":"1978","journal-title":"J Antibiot (Tokyo)"},{"issue":"S 78","key":"ref25","first-page":"45","article-title":"Incidence of multi-resistance in gram-negative bacterial isolates from intensive care units in Belgium: a surveillance study","volume":"78","author":"L Verbist","year":"1991","journal-title":"Scand J Infect Dis Suppl"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/17843286.1998.11754138","article-title":"on behalf of a Belgian Multicenter study group. A multicenter survey of antimicrobial resistance in gram-negative isolates from Belgian intensive care units in 1994\u20131995","volume":"53","author":"Y Glupczynski","year":"1998","journal-title":"Acta Clin Belg"},{"issue":"08","key":"ref27","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.1995.03530080055041","article-title":"The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study","volume":"274","author":"J L Vincent","year":"1995","journal-title":"JAMA"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF01695658","article-title":"Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study","volume":"15","author":"R C Spencer","year":"1996","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/BF01699228","article-title":"Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study)","volume":"22","author":"V Jarlier","year":"1996","journal-title":"Intensive Care Med"},{"key":"ref30","first-page":"21","article-title":"Resistance to isepamicin, amikacin and gentamicin in gram-negative bacteria","volume":"21","author":"E Kans\u0131z","year":"2007","journal-title":"Infeks Derg"}],"container-title":["Journal of Laboratory Physicians"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1761928.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T08:21:30Z","timestamp":1703406090000},"score":1,"resource":{"primary":{"URL":"https:\/\/jlabphy.org\/in-vitro-activity-of-isepamicin-against-gram-negative-bacteria-in-comparison-to-other-aminoglycosides-routinely-used-at-a-teaching-hospital-in-northern-india\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":30,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2023,8,2]]},"published-print":{"date-parts":[[2023,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1761928","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0974-2727","0974-7826"],"issn-type":[{"value":"0974-2727","type":"print"},{"value":"0974-7826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]}}}